A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
PHASE2CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
October 31, 2012
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
Conditions
Diabetes Mellitus Type 2
Interventions
DRUG
aleglitazar
150 mcg orally daily, 6 weeks
DRUG
placebo
orally daily, 6 weeks
Trial Locations (1)
OX3 9DU
Oxford
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01680978 - A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease | Biotech Hunter | Biotech Hunter